Cell Projects licenses Electroporation Technologies from Queen’s University, Canada
News Oct 15, 2008
Cell Projects has entered into a wide ranging commercial license and joint development agreement with Queen’s University, Kingston, Ontario, Canada, covering several new Electroporation platform technologies for Adherent and InSitu Cell Electroporation.
The technology allows DNA, peptides, siRNA and many other molecules to be gently transported into cultured, adherent cells while the cells are still attached to their growing surface. The data shows dramatic improvements of sensitivity and operation over existing methodologies.
Tom Hole MD at Cell Projects says “the InSitu technology will enable a greater understanding of specific cellular activities that to date have been difficult to analyze yet are known to be important in further understanding the mechanism of cancer, and other biological problems”.
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE
The Exercise Regime of the Future Needs to Check Your GenesNews
Forget protein bars - genes may be central to the exercise regimes of the future, as scientists track down gene changes which occur in response to exercise.READ MORE